Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Networking and learning resources Hep B Media
1
1 Like
2

Hi @Nawab,

This is an excellent development because it says that Amoytop Biotech is confident that pevifsovir (ALG-000184, the best of the CAMs in clinical trials) will reach the market and be widely used.

John.

3 Likes
3

Dear @john.tavis,

Yes, this drug looks very promising. 2026 looks a very promising year for hepatitis drugs. I hope functional cure will be available before 2030 to majority of the people around the world.

1 Like